Las Vegas, NV -- (SBWIRE) -- 12/17/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Peregrine Pharmaceuticals (NASDAQ:PPHM), LifeVantage Corp (NASDAQ:LFVN), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Orexigen Therapeutics, Inc. (NASDAQ:OREX)
Peregrine Pharmaceuticals (NASDAQ:PPHM) managed to keep its fall at -0.79% on below -normal volume of 1.03M shares. The stock settled at $1.26 after floating in a range of $1.26 to $1.31. Its latest price has reached market capitalization of $202.81 million. Its 52-week range has been $1.11 to $2.78. Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of monoclonal antibodies focused on the treatment and diagnosis of cancer.
Has PPHM Found The Bottom and Ready To Move Up? Find Out Here
LifeVantage Corp (NASDAQ:LFVN) traded down on a volume of 3 million, higher/lower than its standard daily volume. Shares have dropped -0.99% to $1.50. Over the last twelve months, the stock has lost-33.7% and faced a worst price of $1.37. Lifevantage Corporation (Lifevantage) is engaged in the identification, research, development, manufacture and distribution of advanced nutraceutical dietary supplements, including its product, Protandim, the Nrf2 Synergizer and its anti-aging skin care product, LifeVantage TrueScience. The Company focuses its ongoing internal research efforts on oxidative stress solutions, particularly the activation of nuclear factor (erythroid-derived 2)-like 2, also known as Nrf2, as it relates to health-related disorders.
Has LFVN Found The Bottom And Ready To Gain Momentum? Find Out Here
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) settled -1.75% higher at $1.68 on above-normal volume of 1M shares during the last trading day. The stock has its 12-month high at $8.94 and 52-week low price was $1.53. It traded in a range of $1.61 to $1.71 during the last trading day. AVEO Pharmaceuticals, Inc. is a cancer therapeutics company discovering, developing and commercializing targeted cancer therapies.
Will AVEO Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Orexigen Therapeutics, Inc. (NASDAQ:OREX) was down on low volume, trading at a volume of 1M versus its average daily volume of 2.75 million shares. At $5.51, the stock has attained market capitalization of 558.57 million. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
Why Should Investors Buy OREX After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)